Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells

Paterna, A. and Kincses, Annamária and Spengler, Gabriella and Mulhovo, S. and Molnár, József (2017) Dregamine and tabernaemontanine derivatives as ABCB1 modulators on resistant cancer cells. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 128. pp. 247-257. ISSN 0223-5234

Text 3183602_Paterna_A_EJMC_1_s2.0_S0223523417300612_main_u.pdf Restricted to Repository staff only Download (849kB) | Request a copy

Abstract

Dregamine (1) and tabernaemontanine (2), two epimeric monoterpene indole alkaloids isolated in large amount from the roots of the African plant Tabernaemontana elegans, were derivatized, yielding ten imine derivatives, as previously described (3-12). In the present study, aiming at increasing the pool of analogues for establishing structure-activity relationships (SAR), compounds 1 and 2 were further submitted to several chemical transformations, yielding thirteen new derivatives (13-25). Their structures were assigned by spectroscopic methods, including 1D and 2D NMR experiments. Compounds 1-25 were evaluated for their effects on the reversion of multidrug resistance (MDR) in cancer cells mediated by P-glycoprotein (P-gp/ABCB1), through combination of functional and chemosensitivity assays, using a human ABCB1-transfected mouse T-lymphoma cell model. SAR analysis showed that different substituents at C-3 and at the indole nitrogen led to different ABCB1 modulatory effects. When compared to the parent compounds, a remarkable enhancement in MDR reversal activity was found for derivatives sharing a new aromatic moiety. Thus, the strongest ability as MDR reversers, and a manifold activity when compared to verapamil, was found for compound 8, the epimeric compounds 9 and 10, and compound 15, bearing pyrazine, bromo-pyridine, and methoxybenzyloxycarbonyl moieties, respectively. In drug combination assays, all compounds tested were revealed to interact synergistically with doxorubicin. Collectively, the results indicate that some of these derivatives may be promising leads for overcoming MDR in cancer.

Actions (login required)

Edit Item